JUPITER, Fla., Jan. 03, 2018 (GLOBE NEWSWIRE) --
Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), a global
biotechnology company focused on the development and large-scale
manufacture of low cost, better performing biologic vaccines and
drugs at flexible commercial scales, today announced the
appointment of Barry Buckland, Ph.D., to its Board of Directors,
effective January 3rd, 2018.
Dr. Buckland spent 29 years at Merck where he
served in a number of senior R&D leadership roles. His last
position was serving as Vice President Bioprocess R&D, Merck
Research Laboratories focusing on fermentation and bioprocess
development and the commercial manufacturing of
biologics.
“We are very excited that Dr. Buckland has
joined Dyadic’s board of directors,” said Mark Emalfarb, Dyadic’s
CEO. “His extensive background and experience in biological process
development and commercialization, especially for vaccines,
complement existing board member Dr. Arindam Bose’s expertise in
externalized novel biopharmaceutical and biosimilar development,
thereby providing the Company with invaluable expertise, insight
and guidance for our research and commercial initiatives.” Mr.
Emalfarb further commented, “Dr. Buckland has an extensive global
network of business and research relationships that we expect will
help us accelerate the introduction and adoption of our C1
technology by the pharmaceutical and biotech industry for use in
the development and manufacture of biologic vaccines and
drugs.”
Chairman of the Board, Michael Tarnok, stated,
“Dr. Buckland is an ideal addition to Dyadic's team as we work to
further commercialize our C1 technology platform."
Dr. Buckland commented, “I am truly excited to
join the Dyadic team; the range of applications of Dyadic’s highly
productive C1 microbial platform can be further extended using the
rapidly developing tools of Synthetic Biology. This has the
potential to become the platform of choice for manufacturing
protein based biologics because of speed of development and low
cost of goods.”
Currently, Dr. Buckland is the Executive
Director, NIIMBL (National Institute for Innovation in
Manufacturing Biopharmaceuticals) – a recently launched flagship US
private-public sector partnership. In addition, Dr. Buckland also
serves as a consultant and on Scientific Advisory Boards at various
companies and institutions.
Prior positions held by Dr. Buckland at Merck
included: Exec. Director, Bioprocess R&D, Merck Research
Laboratories (1993-1996), Senior Director, Bioprocess R&D,
Merck Research Laboratories (1990-1993), Director, Biochemical
Process R&D, Merck Research Laboratories (1986-1990) and
Director Fermentation Pilot Plant Merck Research Laboratories
(1980-1986) Dr. Buckland began his career as a Biochemical Engineer
at Abbott Laboratories and was a Senior Biochemical Engineer at
Lederle Laboratories. He received a Ph.D. and MSc in
Biochemical engineering from University College London, UK and a
BSc Chemical Engineering from Manchester University,
UK.
In recognition of his outstanding professional
accomplishments Dr. Buckland was elected a Member of the
prestigious US National Academy of Engineering. In addition, he is
a Fellow of the American Institute of Medical and Biological
Engineering (AIMBE) as well as of University College, London. His
other accolades include: American Chemical Society (ACS) Marvin
Johnson Award for Biotechnology; Gold Medal Lecture, International
Institute of Biotechnology, London; Donald Medal, UK Institute of
Chemical Engineering; as well as the Merck Board of Directors award
for leading process development, regulatory approval and launch of
4 major new vaccines. Dr. Buckland was selected by the American
Institute of Chemical Engineering (AIChE) as one of the “One
Hundred Chemical Engineers of the Modern Era” (defined as from
World War II to the present) and Awarded Discoverers Award by the
Pharmaceutical Research and Manufacturers of America (PhRMA) for
role in discovery and development of Gardasil.
About Dyadic International,
Inc.
Dyadic International, Inc. is a global
biotechnology company which is developing what it believes will be
a potentially significant biopharmaceutical gene expression
platform based on the fungus Myceliophthora thermophila,
nicknamed C1. The C1 microorganism, which enables the development
and large scale manufacture of low cost proteins, has the potential
to be further developed into a safe and efficient expression system
that may help speed up the development, lower production costs and
improve the performance of biologic vaccines and drugs at flexible
commercial scales. Dyadic is using the C1 technology and
other technologies to conduct research, development and commercial
activities for the development and manufacturing of human and
animal vaccines, monoclonal antibodies, biosimilars and/or
biobetters, and other therapeutic proteins. Dyadic pursues research
and development collaborations, licensing arrangements and other
commercial opportunities with its partners and collaborators to
leverage the value and benefits of using these technologies in the
development and manufacture of biopharmaceuticals. In particular,
as the aging population grows in developed and undeveloped
countries, Dyadic believes the C1 technology may help bring
biologic drugs to market faster, in greater volumes, at lower cost,
and with new properties to drug developers and manufacturers and,
hopefully, improve access and cost to patients and the healthcare
system, but most importantly save lives.
Please visit Dyadic’s website at www.dyadic.com
for additional information, including details regarding Dyadic’s
plans for its biopharmaceutical business.
Dyadic trades on the OTCQX tier of the OTC
marketplace. Investors can find real-time quotes, market
information and financial reports for Dyadic in the Company’s
annual and quarterly reports which are filed with the OTC markets.
Please visit the OTC markets website at
www.otcmarkets.com/stock/DYAI/quote.
Safe Harbor Regarding Forward-Looking
Statements
Certain statements contained in this press
release are forward-looking statements within the meaning of the
federal securities laws. These forward-looking statements involve
risks, uncertainties and other factors that could cause Dyadic’s
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Investors
are urged to consider these factors carefully in evaluating the
forward-looking statements and are cautioned not to place undue
reliance on such forward-looking statements. Any forward-looking
statements speak only as of the date of this press release and,
except as required by law, Dyadic expressly disclaims any intent or
obligation to update or revise any forward-looking statements to
reflect actual results, any changes in expectations or any change
in events. Factors that could cause results to differ materially
include, but are not limited to: (1) general economic, political
and market conditions; (2) our ability to carry out and implement
our biopharmaceutical research and business plans and strategic
initiatives; (3) Dyadic’s ability to retain and attract employees,
consultants, directors and advisors; (4) our ability to implement
and successfully carry out Dyadic’s and third parties research and
development efforts; (5) our ability to obtain new license and
research agreements; (6) our ability to maintain our existing
access to, and/or expand access to third party contract research
organizations in order to carry out our research projects for
ourselves and third parties; (7) competitive pressures and reliance
on key third-party and related party research organizations,
customers and collaborators; and (8) other factors discussed in
Dyadic’s publicly available filings, including information set
forth under the caption “Risk Factors” in our December 31, 2016,
Annual Report filed with OTC Markets on March 24, 2017. New risks
and uncertainties arise from time to time, and it is impossible for
us to predict these events or how they may affect us.
Contact:
Dyadic International, Inc.
Thomas L. Dubinski
Chief Financial Officer
Phone: 561-743-8333
Email: tdubinski@dyadic.com
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Dyadic (NASDAQ:DYAI)
Historical Stock Chart
From Sep 2023 to Sep 2024